If You Invested in CELL SOURCE INC (CLCS)
Looking for the current price? See the CLCS quote & overviewWhat $1,000 or $10,000 in CLCS Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Oct 21, 2015 |
|---|---|---|---|---|
| $1,000 | $1,252 +25% | $381 -62% | $565 -44% | $400 -60% |
| $10,000 | $12,521 +25% | $3,813 -62% | $5,645 -44% | $4,002 -60% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-10-19. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for CLCS$1,000 Investment Over Time
CLCS vs S&P 500Year-by-Year Returns
CLCS annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2015 | $1.22 | $1.25 | +2.5% | +2.5% |
| 2016 | $1.25 | $0.45 | -64.0% | -63.1% |
| 2017 | $0.45 | $0.27 | -40.0% | -77.9% |
| 2018 | $0.27 | $0.75 | +177.8% | -38.5% |
| 2019 | $0.75 | $1.10 | +46.7% | -9.8% |
| 2020 | $1.10 | $2.00 | +81.8% | +63.9% |
| 2021 | $2.00 | $1.2805 | -36.0% | +5.0% |
| 2022 | $1.2805 | $0.85 | -33.6% | -30.3% |
| 2023 | $0.85 | $0.46 | -45.9% | -62.3% |
| 2024 | $0.46 | $0.35 | -23.9% | -71.3% |
| 2025 | $0.35 | $0.50 | +42.9% | -59.0% |
| 2026 | $0.50 | $0.4883 | -2.3% | -60.0% |
About CELL SOURCE INC
Healthcare · OTC
Cell Source, Inc. develops Veto Cell-based immunotherapy technologies for immune tolerance management in transplantation and cell therapy. The company is quoted on the OTCQB under the symbol CLCS and focuses on donor-derived cellular approaches intended to reduce immune rejection in mismatched donor stem cell transplants, organ transplants, and allogeneic immunotherapy products.
The company's central platform is its proprietary Veto Cell technology, an allogeneic cell-therapy approach designed to manage immune response so that transplanted cells can be tolerated by the recipient. Cell Source has described the platform as applicable to stem cell transplantation for malignant and non-malignant hematologic diseases, including settings where a fully matched donor may not be available. The company also links the platform to potential companion-cell use with cellular therapies such as CAR-T and NK-cell approaches, where immune rejection and graft-versus-host disease are major technical barriers.
Veto Cell platform and development focus
Cell Source's development model centers on translating Veto Cells from preclinical and early clinical research into cellular therapy applications. The technology is exclusively licensed from The Weizmann Institute of Science in Israel. Reported applications include mismatched donor bone marrow and stem cell transplantation, treatment approaches for hematologic malignancies and non-malignant blood diseases, and immune-tolerance support for donor-derived CAR-T therapy. The company's recent scientific communications have addressed natural killer cell-mediated rejection, a mechanism that can limit allogeneic cell therapies.
The company has reported both clinical and preclinical work around its platform. Clinical work has involved Veto Cell use in stem cell transplants for malignant and non-malignant hematologic diseases at The University of Texas MD Anderson Cancer Center. Preclinical publications and company updates have also described Veto Cell-based bone marrow transplant protocols in models of sickle cell disease and other transplant settings.
Intellectual property and research orientation
Cell Source has announced U.S. patent activity covering Veto Cell technology, including patents titled Veto Cells Generated from Memory T Cells and Methods of Transplantation and Disease Treatment. These patent disclosures relate to Veto Cells that are intended to support patient acceptance of transplanted cells, address graft rejection and graft-versus-host disease, and act as companion cells with other cellular therapy modalities.
As a development-stage cell therapy company, Cell Source's business is organized around proprietary technology licensing, research collaborations, clinical translation, patent protection, and scientific presentation of immune-tolerance data. Its operating identity is tied to Veto Cell-based immunotherapy rather than commercial sales of approved therapeutics.
Similar Stocks
See how related companies performed
Frequently Asked Questions
CELL SOURCE INC investment returns
How much would $1,000 invested in CELL SOURCE INC be worth today?
If you invested $1,000 in CELL SOURCE INC (CLCS) 10 years ago on 2016-10-20, your investment would be worth $565 as of 2026-10-19, a -43.5% price return without dividends, growing at a compounded rate of -5.6% per year (CAGR).
Has CELL SOURCE INC outperformed the S&P 500?
Over the past 10 years, CLCS returned -43.5% compared to +258.4% for the S&P 500, underperforming the benchmark by 301.9 percentage points.
What is CELL SOURCE INC's average annual return?
The compound annual growth rate (CAGR) of CLCS’s share price over the past 10 years is -5.6%, without dividends. Individual years vary a great deal, and CLCS’s best recent full year was 2018 (+177.8%) while the worst was 2016 (-64.0%).
For informational and educational purposes only, not investment advice.
